These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 24612173)

  • 41. Pattern of nucleotide variants of TP53 and their correlation with the expression of p53 and its downstream proteins in a Sri Lankan cohort of breast and colorectal cancer patients.
    Manoharan V; Karunanayake EH; Tennekoon KH; De Silva S; Imthikab AIA; De Silva K; Angunawela P; Vishwakula S; Lunec J
    BMC Cancer; 2020 Jan; 20(1):72. PubMed ID: 32000721
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Analyses of p53 mutations in breast cancers with a combined use of yeast functional assay and immunohistochemical staining].
    Takahashi M
    Hokkaido Igaku Zasshi; 1998 May; 73(3):275-86. PubMed ID: 9719952
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Neuroendocrine differentiation correlates with hormone receptor expression and decreased survival in patients with invasive breast carcinoma.
    Kwon SY; Bae YK; Gu MJ; Choi JE; Kang SH; Lee SJ; Kim A; Jung HR; Kang SH; Oh HK; Park JY
    Histopathology; 2014 Apr; 64(5):647-59. PubMed ID: 24117859
    [TBL] [Abstract][Full Text] [Related]  

  • 44. p53 in node-negative breast carcinoma: an immunohistochemical study of epidemiologic risk factors, histologic features, and prognosis.
    Rosen PP; Lesser ML; Arroyo CD; Cranor M; Borgen P; Norton L
    J Clin Oncol; 1995 Apr; 13(4):821-30. PubMed ID: 7707107
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Association of GATA3, P53, Ki67 status and vascular peritumoral invasion are strongly prognostic in luminal breast cancer.
    Jacquemier J; Charafe-Jauffret E; Monville F; Esterni B; Extra JM; Houvenaeghel G; Xerri L; Bertucci F; Birnbaum D
    Breast Cancer Res; 2009; 11(2):R23. PubMed ID: 19405945
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Breast cancers presenting luminal B subtype features show higher discordant human epidermal growth factor receptor 2 results between immunohistochemistry and fluorescence in situ hybridization.
    Park S; Park HS; Koo JS; Yang WI; Kim SI; Park BW
    Cancer; 2012 Feb; 118(4):914-23. PubMed ID: 21800290
    [TBL] [Abstract][Full Text] [Related]  

  • 47. TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting.
    Fountzilas G; Giannoulatou E; Alexopoulou Z; Zagouri F; Timotheadou E; Papadopoulou K; Lakis S; Bobos M; Poulios C; Sotiropoulou M; Lyberopoulou A; Gogas H; Pentheroudakis G; Pectasides D; Koutras A; Christodoulou C; Papandreou C; Samantas E; Papakostas P; Kosmidis P; Bafaloukos D; Karanikiotis C; Dimopoulos MA; Kotoula V
    Oncotarget; 2016 May; 7(22):32731-53. PubMed ID: 27129168
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Basal-HER2 phenotype shows poorer survival than basal-like phenotype in hormone receptor-negative invasive breast cancers.
    Liu H; Fan Q; Zhang Z; Li X; Yu H; Meng F
    Hum Pathol; 2008 Feb; 39(2):167-74. PubMed ID: 18045647
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Differential expression of senescence tumour markers and its implications on survival outcomes of breast cancer patients.
    Pare R; Soon PS; Shah A; Lee CS
    PLoS One; 2019; 14(4):e0214604. PubMed ID: 30998679
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prognostic significance of molecular subtype in T1N0M0 breast cancer: Korean experience.
    Kim RG; Kim EK; Kim HA; Koh JS; Kim MS; Kim KI; Lee JI; Moon NM; Ko E; Noh WC
    Eur J Surg Oncol; 2011 Jul; 37(7):629-34. PubMed ID: 21596514
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Thymidylate synthase expression and p21(WAF1)/p53 phenotype of colon cancers identify patients who may benefit from 5-fluorouracil based therapy.
    Sulzyc-Bielicka V; Domagala P; Bielicki D; Safranow K; Domagala W
    Cell Oncol (Dordr); 2014 Feb; 37(1):17-28. PubMed ID: 24277474
    [TBL] [Abstract][Full Text] [Related]  

  • 52. High Ki67/BCL2 index is associated with worse outcome in early stage breast cancer.
    Min KW; Kim DH; Do SI; Pyo JS; Chae SW; Sohn JH; Kim K; Lee HJ; Kim DH; Oh S; Choi SH; Park YL; Park CH; Kwon MJ; Moon KM
    Postgrad Med J; 2016 Dec; 92(1094):707-714. PubMed ID: 27222586
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparisons of p53, KI67 and BRCA1 expressions in patients with different molecular subtypes of breast cancer and their relationships with pathology and prognosis.
    Li Y; Zhang X; Qiu J; Pang T; Huang L; Zeng Q
    J BUON; 2019; 24(6):2361-2368. PubMed ID: 31983107
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Early onset HER2-positive breast cancer is associated with germline TP53 mutations.
    Melhem-Bertrandt A; Bojadzieva J; Ready KJ; Obeid E; Liu DD; Gutierrez-Barrera AM; Litton JK; Olopade OI; Hortobagyi GN; Strong LC; Arun BK
    Cancer; 2012 Feb; 118(4):908-13. PubMed ID: 21761402
    [TBL] [Abstract][Full Text] [Related]  

  • 55. p53 and Ki-ras as prognostic factors for Dukes' stage B colorectal cancer.
    Bouzourene H; Gervaz P; Cerottini JP; Benhattar J; Chaubert P; Saraga E; Pampallona S; Bosman FT; Givel JC
    Eur J Cancer; 2000 May; 36(8):1008-15. PubMed ID: 10885605
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion.
    Moll UM; Riou G; Levine AJ
    Proc Natl Acad Sci U S A; 1992 Aug; 89(15):7262-6. PubMed ID: 1353891
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Expression of aryl hydrocarbon receptor in relation to p53 status and clinicopathological parameters in breast cancer.
    Li ZD; Wang K; Yang XW; Zhuang ZG; Wang JJ; Tong XW
    Int J Clin Exp Pathol; 2014; 7(11):7931-7. PubMed ID: 25550834
    [TBL] [Abstract][Full Text] [Related]  

  • 58. HER3 status by immunohistochemistry is correlated with poor prognosis in hormone receptor-negative breast cancer patients.
    Bae SY; La Choi Y; Kim S; Kim M; Kim J; Jung SP; Choi MY; Lee SK; Kil WH; Lee JE; Nam SJ
    Breast Cancer Res Treat; 2013 Jun; 139(3):741-50. PubMed ID: 23722313
    [TBL] [Abstract][Full Text] [Related]  

  • 59. p53 gene mutations and expression of p53 and mdm2 proteins in invasive breast carcinoma. A comparative analysis with clinico-pathological factors.
    Günther T; Schneider-Stock R; Rys J; Niezabitowski A; Roessner A
    J Cancer Res Clin Oncol; 1997; 123(7):388-94. PubMed ID: 9260591
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Neutrophil gelatinase-associated lipocalin (NGAL) predicts response to neoadjuvant chemotherapy and clinical outcome in primary human breast cancer.
    Wenners AS; Mehta K; Loibl S; Park H; Mueller B; Arnold N; Hamann S; Weimer J; Ataseven B; Darb-Esfahani S; Schem C; Mundhenke C; Khandan F; Thomssen C; Jonat W; Holzhausen HJ; von Minckwitz G; Denkert C; Bauer M
    PLoS One; 2012; 7(10):e45826. PubMed ID: 23056218
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.